0.00Open0.00Pre Close0 Volume0 Open Interest4.00Strike Price0.00Turnover1537.28%IV-47.16%PremiumDec 13, 2024Expiry Date3.57Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8732Delta0.0281Gamma1.74Leverage Ratio-0.5944Theta0.0001Rho1.52Eff Leverage0.0010Vega
Recursion Pharmaceuticals Stock Discussion
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class Cdk7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
No comment yet